Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
14.72
-0.71 (-4.60%)
At close: Aug 11, 2026, 4:00 PM EDT
14.75
+0.03 (0.20%)
After-hours: Aug 11, 2026, 7:53 PM EDT
Silence Therapeutics Revenue
Silence Therapeutics had revenue of $624.83K in the twelve months ending June 30, 2026, down -97.63% year-over-year. In the year 2025, Silence Therapeutics had annual revenue of $568.83K, down -98.66%.
Revenue (ttm)
$624.83K
Revenue Growth
-97.63%
P/S Ratio
1,130.54
Revenue / Employee
$6,989
Employees
88
Market Cap
695.28M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 568.83K | -41.89M | -98.66% |
| Dec 31, 2024 | 42.45M | 10.81M | 34.17% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.87M | 29.01% |
| Dec 31, 2021 | 16.78M | 9.29M | 124.07% |
| Dec 31, 2020 | 7.49M | 7.17M | 2,215.11% |
| Dec 31, 2019 | 323.57K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 21.62K | -928.69K | -97.72% |
| Dec 31, 2016 | 950.31K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 23.37K | -170.40K | -87.94% |
| Dec 31, 2013 | 193.77K | -70.63K | -26.71% |
| Dec 31, 2012 | 264.40K | -812.57K | -75.45% |
| Dec 31, 2011 | 1.08M | -2.61M | -70.75% |
| Dec 31, 2010 | 3.68M | 893.28K | 32.03% |
| Dec 31, 2009 | 2.79M | -435.52K | -13.51% |
| Dec 31, 2008 | 3.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Phathom Pharmaceuticals | 239.66M |
| REGENXBIO | 174.48M |
| Zevra Therapeutics | 136.07M |
| Gyre Therapeutics | 109.82M |
| CytomX Therapeutics | 18.30M |
| Crescent Biopharma | 11.88M |
| Allogene Therapeutics | 22.00K |
SLN News
- 3 hours ago - Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering - Business Wire
- 18 hours ago - Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley - TheFly
- 1 day ago - Silence Therapeutics files to sell $150M in ADS’s - TheFly
- 1 day ago - Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares - Business Wire
- 1 day ago - Silence Therapeutics Transcript: Study result - Transcripts
- 1 day ago - Silence Therapeutics Press release: Study result - Filings
- 1 day ago - Silence Therapeutics Slides: Study result - Filings
- 1 day ago - Silence announces results from Phase 2 SANRECO trial met primary endpoint - TheFly